New 3D organoid model of pancreas developed from human stem cells 29 April 2021 | By Victoria Rees (Drug Target Review) Researchers have developed the first 3D organoid models of the pancreas that includes both the acinar and ductal structures.
Antibody cocktail shown to neutralise SARS-CoV-2 variants of concern 28 April 2021 | By Victoria Rees (Drug Target Review) A new antibody cocktail made from three mAbs neutralised several SARS-CoV-2 variants in pre-clinical studies.
First comprehensive single-cell atlas of human teeth compiled 28 April 2021 | By Victoria Rees (Drug Target Review) Using single-cell sequencing technology, researchers have gained insight into the interactions of dental pulp and periodontal cells of teeth.
Sanguinarine shows promise against triple-negative breast cancer 28 April 2021 | By Victoria Rees (Drug Target Review) A new study in cell cultures has shown that the sanguinarine plant compound could be used to treat people with triple-negative breast cancer.
Hepatitis C drugs shown to boost remdesivir’s activity against SARS-CoV-2 28 April 2021 | By Victoria Rees (Drug Target Review) Four hepatitis C drugs have demonstrated promise as boosters to increase the efficacy of remdesivir against SARS-CoV-2 by as much as tenfold.
Study points to treatment approaches for advanced small-cell lung cancer 27 April 2021 | By Victoria Rees (Drug Target Review) Having sequenced samples of advanced small-cell lung cancer, researchers have identified patterns linked to resistance to certain therapies.
AI platform developed to reveal how bacteria infect intestines 27 April 2021 | By Victoria Rees (Drug Target Review) A new artificial intelligence (AI) method has been created to uncover which proteins enable bacteria to infect human intestines.
Nanobody cocktail shown to block SARS-CoV-2 infection in mouse models 27 April 2021 | By Victoria Rees (Drug Target Review) Researchers have used cryo-EM to show that a new nanobody cocktail can bind to the S protein of SARS-CoV-2, neutralising the coronavirus.
Inhibiting METTL3 enzyme combats acute myeloid leukaemia in mice 27 April 2021 | By Victoria Rees (Drug Target Review) Scientists have developed a drug called STM2457 which inhibits a key enzyme involved in acute myeloid leukaemia.
UK Government launches Pandemic Preparedness Partnership group 26 April 2021 | By Victoria Rees (Drug Target Review) The UK has launched the Pandemic Preparedness Partnership which will advise the G7 Presidency how to reduce vaccine development time from 300 to 100 days.
Role of macrophages in blood flow regulation after tissue damage revealed 26 April 2021 | By Victoria Rees (Drug Target Review) Researchers have shown in mice that macrophages play a role in controlling blood flow and healing following tissue damage.
Free AI platform created to analyse microscopy images 26 April 2021 | By Victoria Rees (Drug Target Review) An AI software called ZeroCostDL4Mic has been developed by researchers to enable other scientists to analyse images from microscopy studies.
Scientists call for awareness of unintended mutations from CRISPR 26 April 2021 | By Victoria Rees (Drug Target Review) Scientists have said that researchers need to be more aware of unintended mutations to human embryos following CRISPR-Cas9 genome editing.
DNA vaccine protects non-human primates against MERS, study shows 23 April 2021 | By Victoria Rees (Drug Target Review) A candidate vaccine has shown potential against MERS in non-human primates, when administered intradermally.
Molecule in body that blocks antibody binding to SARS-CoV-2 discovered 23 April 2021 | By Victoria Rees (Drug Target Review) Biliverdin attaches to a region of the SARS-CoV-2 Spike protein, stabilising it so that it is not able to expose its structure to antibodies, a new study has shown.
